PRESS RELEASE
Hyloris Appoints Marieke Vermeersch as VP of Investor Relations and Corporate Communications
Liège, Belgium – 3 February 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals, today announces the appointment of Marieke Vermeersch as Vice President of Investor Relations and Corporate Communications, overseeing Hyloris’ investor, commercial and financial communication activities. Marieke joins the company with over 20 years of experience in the life sciences sector, with a focus on investor relations and financial communications.
Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: “We are very pleased to welcome Marieke to the team. Her extensive skills, experience and knowledge of the sector will be invaluable as we push ahead with our strategy to develop and commercialise high-value products to address unmet medical needs, benefit patients and reduce the burden on healthcare systems around the world.”
Marieke has held a number of senior roles in investor relations, corporate communications and investment banking. From November 2010 she served at Ablynx, first as Director of Investor Relations and Corporate Communications and later as Director Business Development, up to the Company’s acquisition by Sanofi for $4.8 billion in 2018. Prior to this, Marieke was a pharma and biotech investment equity analyst at Degroof Petercam.
Marieke obtained a Masters’ Degree in Bioscience Engineering from the Ghent University, and holds an MBA from Solvay Brussels School.
For more information, please contact:
Hyloris Pharmaceuticals
Stijn Van Rompay, CEO
Marieke Vermeersch, VP Investor Relations and Corporate Communications
+32 (0)4 346 02 07
investorrelations@hyloris.com
Consilium Strategic Communications
Amber Fennell, Chris Welsh
+44 20 3709 5700
hyloris@consilium-comms.com
About Hyloris Pharmaceuticals SA
Based in Liège, Belgium, Hyloris is an innovative specialty biopharma company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system.
Hyloris currently has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialized through its partner AltaThera, and Maxigesic® IV, a non-opioid analgesic product for the treatment of pain, developed with the Company’s partner, AFT Pharmaceuticals. Additionally, Hyloris has 12 product candidates in various stages of development across the Company’s wider portfolio with a focus on intravenous cardiovascular drugs and other potential high value reformulations. Read more at www.hyloris.com. Hyloris stands for “high yield, lower risk” and relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.
Forward-looking statements
Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Attachment
